Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1,898 Mln
Revenue (TTM)
$673 Mln
Net Profit (TTM)
$0 Mln
ROE
-6.1 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
247.7
Industry P/E
--
EV/EBITDA
-6.5
Div. Yield
0 %
Debt to Equity
-16
Book Value
$--
EPS
$-5.8
Face value
--
Shares outstanding
96,629,788
CFO
$-2,527.56 Mln
EBITDA
$-3,583.79 Mln
Net Profit
$-3,308.42 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Ultragenyx (RARE)
| -2.4 | -4.0 | -2.4 | -33.7 | -17.6 | -27.6 | -10.3 |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Ultragenyx (RARE)
| -45.3 | -11.9 | 3.2 | -44.9 | -39.3 | 224.1 | -1.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Ultragenyx (RARE)
|
22.5 | 1,897.5 | 673.0 | -575.0 | -76.5 | -656 | -- | 247.7 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 229.3 | 13,405.2 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 14.6 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 105.4 | 7,603.8 | 0.0 | -425.4 | -- | -36.7 | -- | 6.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America,... Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc. The company was incorporated in 2010 and is headquartered in Novato, California. Address: 60 Leveroni Court, Novato, CA, United States, 94949 Read more
Founder, President, CEO & Director
Dr. Emil D. Kakkis M.D., Ph.D.
Founder, President, CEO & Director
Dr. Emil D. Kakkis M.D., Ph.D.
Headquarters
Novato, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Ultragenyx (RARE) is $22.45 (NASDAQ) as of 02-Apr-2026 19:48 EDT. Ultragenyx (RARE) has given a return of -17.58% in the last 3 years.
Since, TTM earnings of Ultragenyx (RARE) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-4.00
|
-28.72
|
|
2024
|
-7.07
|
15.77
|
|
2023
|
-6.39
|
14.08
|
|
2022
|
-4.59
|
9.22
|
|
2021
|
-12.70
|
6.25
|
The 52-week high and low of Ultragenyx (RARE) are Rs 42.37 and Rs 18.29 as of 05-Apr-2026.
Ultragenyx (RARE) has a market capitalisation of $ 1,898 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Ultragenyx (RARE), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$1.03
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.